S&P Futures
6,004.75 -1.75 (-0.03%) Dow Futures
44,812.00 -14.00 (-0.03%) Nasdaq Futures
20,873.25 -7.00 (-0.03%) Russell 2000 Futures
2,436.70 -14.30 (-0.58%) Crude Oil
69.59 +0.65 (+0.94%) Gold
2,631.70 +13.20 (+0.50%)
Psyence Biomedical Ltd. (PBMWW)
Psyence Biomedical Ltd.
121 Richmond Street West
Penthouse Suite, 1300
Toronto, ON M5H2K1
Canada
416-346-7764
https://www.psyencebiomed.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jody Aufrichtig | Co-Founder, Executive Chairman & Strategic Business Development Officer | 110.3k | N/A | 1974 |
| Dr. Neil Maresky M.D. | CEO & Director | 231.23k | N/A | 1965 |
| Mr. Warwick Ron Corden-Lloyd | Chief Financial Officer | 98.35k | N/A | 1980 |
| Ms. Taryn Vos | General Counsel | N/A | N/A | N/A |
| Ms. Mary-Elizabeth Gifford | Chief of Global Impact | N/A | N/A | N/A |
Description
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Corporate Governance
Psyence Biomedical Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
